Shionogi Co-promotes Flu Diagnostic Kit Along With Peramivir
This article was originally published in PharmAsia News
Executive SummaryOsaka-based Shionogi started co-promoting a flu virus diagnostic kit developed by Tokyo-based Mizuho Medy in Japan. The Quick Chaser Flu A,B can quickly detect the flu virus and will be marketed along with Shionogi's newly launched flu drug Rapiacta (peramivir) injection. The co-promotion deal will enable Shionogi to provide flu patients with a full line of services from detection to treatment. The diagnostic kit is priced at ¥11,000 for 10 uses. (Click here for more - Japanese language
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.